disease activity and lab measurements. RESULTS: 106 papers met our inclusion criteria. Studies were published between 2003 and 2015 and mostly from Europe; 39 included patients starting etanercept, 36 included patients starting rituximab and 32 patients starting tocilizumab. Mean age ranged between 42.9 and 63.3 years. 78.2% were female. The drugs were given in combination with methotrexate and/or other DMARDs in over two thirds of the studies. Mean ± SD disease duration varied between 4 and 17.5 years, baseline disease activity score 28 scores between 4.3 and 7.0, and baseline health assessment questionnaire values between 1 and 2.9. The median proportion of rheumatoid factor positive patients was 76.4%. Reporting of comorbidities and smoking status was generally poor, with only few studies providing detailed data.

CONCLUSIONS: This systematic review of data from observational studies and clinical databases indicates that the characteristics of RA patients starting biologic treatment in the real world are different from those from clinical trials. These observational data will now be compared with clinical trial data but it seems likely that some patient groups were not well represented in the trials.

PMS136 EFFECTIVENESS OF A REFERRAL PROGRAM FOR EARLY ARTHRITIS DIAGNOSIS AT PRIMARY CARE CENTERS IN PORTUGAL - PRELIMINARY RESULTS FROM THE SIAR STUDY

Laires PA1, Dezerto R2, Mesquita R3, Fonseca JS4, Cernadas R3, Miranda LC5, Silva JC6, Costa LL, Nogueira AM7

1Merek Sharp & Dohme, Oeiras, Portugal, 2Centro Hospitalar Lisboa Norte, EPE - Hospital Santa Maria, Lisboa, 3ARS Norte, Oporto, Portugal, 4Instituto Português de Reumatologia, Lisboa, Portugal, 5Garcia de Orta Hospital, Almada, Portugal, 6Hospital São João (Centro Hospitalar de São João), Oporto, Portugal, 7Centro Hospitalar de Alcântara, Lisbon, Portugal, 3ARS Norte, Oporto, Portugal, 4Instituto Português de Reumatologia, Lisboa, Portugal, 5Garcia de Orta Hospital, Almada, Portugal, 6Hospital São João (Centro Hospitalar de São João), Oporto, Portugal

OBJECTIVES: Early diagnosis and treatment of inflammatory arthritis can limit the impact of disease outcomes. We aimed to evaluate the effectiveness of a referral program on the identification of patients with suspected inflammatory arthritis (IA). METHODOLOGY: A retrospective study was conducted at the rheumatology unit of the reference hospital (n=6). The main studied outcome is the correct diagnosis of inflammatory arthritis / rheumatoid arthritis confirmed by the rheumatologist of the reference hospital. RESULTS: A total of 125 patients were referred to a rheumatologist (considering 4 hospitals): 61 RSA patients and 64 control patients. Mean age was 48.9 years (range: 19-73) and 88.8% were female (differences not statistically significant between groups). About 14.8% (n=9) of RSA patients and 4.7% (n=3) of controls had a confirmed diagnosis of arthritis (any type) by the rheumatologist (OR=3.5; 95%CI; 0.9-13.7; Chi-square p=0.056). Rate of confirmed rheumatoid arthritis was 4.9% in RSA patients and 1.6% in controls (p=0.287). The majority of the patients (82%) were referred in the 4 months after educational session (month 3.63%, month 6 9.67%). CONCLUSIONS: Although the study results still lack statistical significance, this preliminary data already suggests a positive impact of a referral program on the early identification of inflammatory arthritis. Further research is needed to verify this first pilot study and consider by healthcare deciders in order to improve health outcomes in inflammatory arthritis.

PMS137 A WEB-BASED SURVEY TO INVESTIGATE THE EXTENT OF AWARENESS AND UNDERSTANDING FOR BIOSIMILAR AMONG JAPANESE PHYSICIANS AND PHARMACISTS

Tanabe K, Sugimoto N, Fujimoto Y

Pfizer Japan Inc, Tokyo, Japan

OBJECTIVES: Several biosimilar products have been developed and marketed in Japan. However, the degree of understanding of biosimilars among healthcare professionals is uncertain. The objective of this study was to investigate the extent of awareness and understanding of biosimilars among Japanese physicians and pharmacists. METHODS: This was a non-interventional, web-based survey conducted in May 2015. Japanese physicians (rheumatologists/oncologists) and pharmacists voluntarily participated and provided their thoughts via questionnaires. Rheumatologists who have seen >= 30 rheumatoid arthritis patients/month on average and have prescribed biologics (Remicade/Humira, etc.) to at least one patient, and oncologists who have seen >= 30 cancer patients/year with use of biologics (Rituxan/Herceptin, etc.) to at least one patient were eligible. RESULTS: Of screened physicians, about 35% have never heard of "biosimilar", whereas 96% of pharmacists were aware of "biosimilar". One hundred rheumatologists, 120 oncologists (30 each for Hematology/Breast/Gastroenterology/Respiratory) and 30 pharmacists who met the criteria and were aware of biosimilar were analyzed for a further questionnaire. 73% of rheumatologists and 82% of oncologists recognized that biosimilars "are relatively less expensive" and 62% of physicians simply answered "substantial savings on procuring drug". 58% of rheumatologists showed awareness of biosimilar, whereas 73% of oncologists showed prescription interest. The main reason behind this was "reduction of burden on patients", followed by "confirmed similarity in efficacy/safety". Physicians with little intention to prescribe biosimilars showed strong concerns for similarity to the innovator (>70%) and insufficient clinical data in efficacy/safety perspectives. Similarities in clinical efficacy/safety were more emphasized compared to structural and functional similarities in biosimilars, depending on the specific drug. CONCLUSIONS: Awareness of biosimilars amongst Japanese physicians was still low with a strong leaning toward burden on patients and sufficient clinical data to confirm the similarity. Providing learning opportunities for general tenets of similarity and its development pathways are vital to increase public recognition of biosimilars.

SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies

PSY1 ASSOCIATION OF ADVERSE EVENTS AND HEALTH SERVICE USAGE WITH TAPENTADOL PROLONGED-RELEASE TREATMENT COMPLEMENTED WITH MORPHINE CONTROLLED-RELEASE (CR) AND OXYCODONE CR: A UK PRIMARY CARE OBSERVATIONAL STUDY

Nazeri G, Morgan CL, Jenkins-Jones SL, Currie GJ, Schootwolter D2

Grimsby, St Leonard’s, UK, 2Southend, Cardiff, UK

OBJECTIVES: This study compared adverse outcomes and resource use in patients treated with tapentadol prolonged-release (PR) with those treated with morphine controlled-release (CR) or oxydodone CR. METHODS: Data were from the Clinical Practice Research Datalink, a database derived from UK primary-care. Patients prescribed tapentadol PR between May 2011 and December 2014 were matched to two groups of controls treated with either morphine CR or oxycodone CR on gender, age, main pain site and if drug was the first opioid prescribed. Rates of adverse events (constipation and nausea/vomiting) were compared by adjusted hazard ratio (aHR). Rates of primary-care contacts, accident and emergency contacts, 2016-2017 for recent clinic letters and 2016-2017 for recent hospital inpatient letters. Episodes of Morbidity Statistics (HES), inpatient admissions were compared using incident rate ratios (IRRs) derived from Poisson regression. RESULTS: 1,176 patients prescribed tapentadol PR were matched to 2,352 patients prescribed morphine CR and 557 (47.4%) to oxycodone CR. Compared with controls, adverse events with tapentadol PR treatment were reduced: aHR=0.643 (95% CI 0.459-0.901; p=0.010) versus morphine CR and 0.505 (0.353-0.763; p=0.001) versus oxycodone CR. Compared with morphine CR, primary-care contacts (IRR=0.817; 0.786-0.850), accident and emergency attendance (0.699; 0.560-0.870) and outpatient letters (0.715; 0.543-0.939) were also reduced. For oxycodone CR, the respective figures were 0.776 (0.706-0.840), 0.840 (0.639-1.03) and 0.594 (0.400-0.739). For the subset of HES-linked patients the rates of inpatient admissions were 0.723 (0.595-0.884) and 0.458 (0.357-0.585) vs. morphine CR and oxycodone CR, respectively. CONCLUSIONS: Tapentadol PR was associated with significantly fewer adverse gastrointestinal events than morphine CR or oxycodone CR. There was also significantly reduced primary- and secondary-care resource use. As with all observational studies, potential bias due to residual confounding and confounding by indication should be considered.

PSY2 CLINICAL AND ECONOMIC BURDEN OF PULMONARY EXACERBATIONS IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION

O’Sullivan AK1, Sigrorovitch JF2, Fang A3, Wagner J1, Hodgkins P1

1Vertex Pharmaceuticals, Boston, MA, USA, 2Analytica Group Inc, Boston, MA, USA, 3University of Colorado, Denver, CO, USA

OBJECTIVES: To assess the clinical and economic burden of pulmonary exacerbations (PEX) in patients with cystic fibrosis (CF) and homozygous for the F508Del (ΔF508/ΔF508) mutation. PEX events involving patients ≤ 12 years old were collected in France, Germany, Italy, Spain, Australia and Canada. Demographics, clinical characteristics, and selected resource utilization were obtained for a 12-month baseline period and a follow-up period ranging from 2-36 months. The primary outcome measure was the frequency of late health interventions and costs. PEX events were assessed overall and by age (12-17, ≥ 18 years) and lung function (percent predicted forced expiratory volume in 1-second [ppFEV1]) ≥ 70%, 41-69%, <40%. Descriptive analyses were conducted. RESULTS: Data for 523 patients were included. Baseline mean ± SD age was 24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%.